AMD's $20M Investment in Absci: Accelerating AI-Driven Drug Discovery

Advanced Micro Devices (AMD) has made a strategic investment of $20 million in Absci, a data-first generative AI drug creation company, through a private investment in public equity (PIPE). This partnership aims to leverage AMD's high-performance computing solutions, including AMD Instinct™ accelerators and ROCm™ software, to power critical AI drug discovery workloads at Absci. The collaboration is expected to enhance Absci's biological modeling capabilities, offering improved performance, reduced infrastructure costs, and faster innovation cycles.



The strategic partnership supports Absci's mission to create better biologics for patients, faster, by providing optimized AI solutions for complex biological modeling. AMD's investment underscores the growing demand for innovative AI applications in drug discovery. The collaboration will showcase the exceptional performance of AMD's Instinct accelerators in addressing complex biological applications, including Absci's proprietary IgDesign1 model, the first in vitro validated inverse folding model for antibody design.



Absci Founder & CEO Sean McClain expressed his enthusiasm for the partnership, stating, "This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available. AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery."

Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD, echoed this sentiment, highlighting the synergies between Absci's cutting-edge AI models and AMD's advanced hardware. "We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed. Absci’s groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads."

The partnership between AMD and Absci has the potential to significantly influence the timeline for drug discovery and development. By leveraging AMD's high-performance computing solutions, Absci can optimize its AI-driven drug discovery workloads, particularly in de novo antibody design models. This optimization can lead to improved performance, reduced infrastructure costs, faster innovation cycles, and validation of Absci's AI models, ultimately contributing to a more efficient and faster drug discovery and development process.

In conclusion, AMD's $20 million investment in Absci, along with the deployment of AMD Instinct accelerators and ROCm software, is set to accelerate AI-driven drug discovery and biopharma adoption of AMD's high-performance computing solutions. This strategic partnership is poised to revolutionize the drug discovery landscape, enabling the creation of better biologics for patients, faster.